| Intravenous artesunate is the most efficacious treatment for severe malaria, but data are limited on its use in pregnancy |
| No associations have been reported between artemisinin use in humans and increased risk of miscarriage, stillbirth, or congenital anomalies |
| The 2010 WHO guidelines recommend using either quinine or artesunate for the treatment of severe malaria in first trimester pregnancies |
| Current data suggest that WHO treatment guidelines should be changed to recommend artesunate as the preferred treatment option for severe malaria in pregnancy during all three trimesters |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.